Op2Lysis is awarded a M€ 0.5 grant from the Programme d’Investissements d’Avenir

Op2Lysis is awarded a M€ 0.5 grant from the Programme d’Investissements d’Avenir

Op2Lysis has obtained a M€ 0.5 grant, following the « Innov Avenir Entreprises » call for projects, which was lauched by the Government and by the Normandy Region as the third round of the Programme d’investissements d’avenir (PIA). This grant will fund almost 50% of the budget to set up a pilot for production and purification of O2L-001, including development of a stable cell line to express O2L-001, which is a key step in the development plan of our drug candidate to treat hemorrhagic stroke patients. This award reflects the increasing support from the Government (through the DIRRECTE), the Normandy Region and bpifrance (which appraised our application) to progress towards the preclinical regulatory development phase and submit a Clinical Trial Application Form in Europe and an IND in the US in the next two years.

 

About the author

Tiffany Le Carff administrator